HERON THERAPEUTICS INC (HRTX)
US4277461020 - Common Stock
HRTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of HRTX have multiple concerns. HRTX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HRTX has reported negative net income.
In the past year HRTX has reported a negative cash flow from operations.
In the past 5 years HRTX always reported negative net income.
In the past 5 years HRTX always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -12.67%, HRTX belongs to the best of the industry, outperforming 85.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.67% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-64.8%
ROA(5y)-59.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HRTX's Gross Margin of 72.19% is amongst the best of the industry. HRTX outperforms 83.72% of its industry peers.
HRTX's Gross Margin has declined in the last couple of years.
HRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.19% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.24%
GM growth 5Y-5.45%
2. Health
2.1 Basic Checks
HRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
HRTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HRTX has been increased compared to 5 years ago.
The debt/assets ratio for HRTX is higher compared to a year ago.
2.2 Solvency
HRTX has an Altman-Z score of -10.81. This is a bad value and indicates that HRTX is not financially healthy and even has some risk of bankruptcy.
HRTX has a worse Altman-Z score (-10.81) than 75.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.81 |
ROIC/WACCN/A
WACC10.19%
2.3 Liquidity
HRTX has a Current Ratio of 2.28. This indicates that HRTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HRTX (2.28) is worse than 72.92% of its industry peers.
HRTX has a Quick Ratio of 1.74. This is a normal value and indicates that HRTX is financially healthy and should not expect problems in meeting its short term obligations.
HRTX has a Quick ratio of 1.74. This is in the lower half of the industry: HRTX underperforms 78.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 1.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 81.25% over the past year.
Looking at the last year, HRTX shows a quite strong growth in Revenue. The Revenue has grown by 12.13% in the last year.
HRTX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.39% yearly.
EPS 1Y (TTM)81.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.35%
Revenue 1Y (TTM)12.13%
Revenue growth 3Y12.76%
Revenue growth 5Y10.39%
Sales Q2Q%4.38%
3.2 Future
HRTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.21% yearly.
Based on estimates for the next years, HRTX will show a quite strong growth in Revenue. The Revenue will grow by 14.69% on average per year.
EPS Next Y85.37%
EPS Next 2Y40.16%
EPS Next 3Y29.15%
EPS Next 5Y20.21%
Revenue Next Year13.8%
Revenue Next 2Y16.26%
Revenue Next 3Y15.37%
Revenue Next 5Y14.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HRTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HRTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as HRTX's earnings are expected to grow with 29.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.16%
EPS Next 3Y29.15%
5. Dividend
5.1 Amount
HRTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HERON THERAPEUTICS INC
NASDAQ:HRTX (12/20/2024, 8:17:08 PM)
After market: 1.54 -0.04 (-2.53%)1.58
+0.05 (+3.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners82.79%
Inst Owner Change-7.06%
Ins Owners0.52%
Ins Owner Change2.67%
Market Cap240.30M
Analysts84.44
Price Target6.12 (287.34%)
Short Float %18.24%
Short Ratio7.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.65%
Min EPS beat(2)-47.06%
Max EPS beat(2)11.76%
EPS beat(4)3
Avg EPS beat(4)25.25%
Min EPS beat(4)-47.06%
Max EPS beat(4)78.21%
EPS beat(8)5
Avg EPS beat(8)13.51%
EPS beat(12)7
Avg EPS beat(12)6.71%
EPS beat(16)9
Avg EPS beat(16)5.39%
Revenue beat(2)0
Avg Revenue beat(2)-7.25%
Min Revenue beat(2)-12.91%
Max Revenue beat(2)-1.59%
Revenue beat(4)2
Avg Revenue beat(4)-0.77%
Min Revenue beat(4)-12.91%
Max Revenue beat(4)8.35%
Revenue beat(8)3
Avg Revenue beat(8)-0.4%
Revenue beat(12)5
Avg Revenue beat(12)-1.41%
Revenue beat(16)6
Avg Revenue beat(16)-4.47%
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)46.66%
EPS NY rev (1m)-12.12%
EPS NY rev (3m)-7.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.89%
Revenue NY rev (1m)-5.07%
Revenue NY rev (3m)-4.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.74 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.91
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.67% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.19% | ||
| FCFM | N/A |
ROA(3y)-64.8%
ROA(5y)-59.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.24%
GM growth 5Y-5.45%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 49.92% | ||
| Cap/Sales | 0.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 1.74 | ||
| Altman-Z | -10.81 |
F-Score4
WACC10.19%
ROIC/WACCN/A
Cap/Depr(3y)72.21%
Cap/Depr(5y)161.21%
Cap/Sales(3y)2.14%
Cap/Sales(5y)3.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.35%
EPS Next Y85.37%
EPS Next 2Y40.16%
EPS Next 3Y29.15%
EPS Next 5Y20.21%
Revenue 1Y (TTM)12.13%
Revenue growth 3Y12.76%
Revenue growth 5Y10.39%
Sales Q2Q%4.38%
Revenue Next Year13.8%
Revenue Next 2Y16.26%
Revenue Next 3Y15.37%
Revenue Next 5Y14.69%
EBIT growth 1Y78.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.63%
OCF growth 3YN/A
OCF growth 5YN/A